ArticleCell division2026
PRRX2-CNTN3 axis promotes epithelial-to-mesenchymal transition and metastasis in colorectal cancer.
Article in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study investigates the role of CNTN3 in colorectal cancer (CRC) progression and its transcriptional regulation by PRRX2, exploring their potential contributions to epithelial-to-mesenchymal transition (EMT) and metastasis.
methodsBioinformatics analysis of CRC datasets identified differentially expressed genes. CNTN3 expression was validated using qPCR, Western blotting, and immunohistochemistry. Functional assays, including cell proliferation, apoptosis, migration, and invasion assays, as well as the detection of EMT markers, assessed the oncogenic role of CNTN3. Chromatin immunoprecipitation and dual-luciferase assays were performed to examine PRRX2-mediated transcriptional regulation of CNTN3. Knockdown and rescue experiments elucidated the functional interplay between PRRX2 and CNTN3. Xenograft tumors were generated for in vivo verification.
resultsCNTN3 expression was significantly elevated in CRC tissues and cell lines, correlating with tumor metastasis and advanced clinical stages. CNTN3 promoted CRC cell proliferation, inhibited apoptosis, and enhanced EMT, migration, and invasion in vitro. PRRX2 was found to bind to the CNTN3 promoter. PRRX2 knockdown reduced CNTN3 expression, reversed EMT marker alterations, and suppressed metastatic phenotypes.
conclusionThese findings suggest that the PRRX2-CNTN3 axis may serve as a key mechanism driving CRC malignancy. This study indicates that CNTN3 functions as a putative oncogene in CRC, with its expression regulated by PRRX2, providing mechanistic insights into EMT and metastasis. The PRRX2-CNTN3 axis emerges as a potential therapeutic target for mitigating CRC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.